Do you want to read an article? Please log in or register.
NIAGARA: Perioperative durvalumab demonstrates broad EFS benefit across molecular subtypes of muscle-invasive bladder cancer
Genitourinary Cancer
ESMO 2026
Related content
Genitourinary Cancer
Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
Int J Cancer
Mangold MH, Baumann G, Wieland VLS, Carl N, Renner LV, Studier-Fischer A, Menold H, Zschäbitz S, Wessels F, Westhoff N, Michel MS, Kowalewski KF, Haney-Aubert CM
doi: 10.1002/ijc.70525
ESMO 2026
Genitourinary Cancer
KEYNOTE-905: Perioperative enfortumab vedotin plus pembrolizumab improves outcomes in cisplatin-ineligible patients with muscle-invasive bladder cancer
Genitourinary Cancer
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
Eur Urol
Gupta S, Li R, Hensley PJ, Daneshmand S, Faltas BM, Grivas P, Lobo N, Mir MC, Meeks JJ, Mouw KW, Moschini M, Necchi A, Oualla K, Pohar KS, Rosenberg JE, Schmidt B, Siefker-Radtke AO, Steinberg GD, Stenzl A, Buckley RJ, Kamat AM
doi: 10.1016/j.eururo.2026.01.029
Genitourinary Cancer
Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19
J Clin Oncol
Cathomas R, Petrausch U, Hayoz S, Spahn M, Bubendorf L, Schäuble K, Strebel RT, Niederberger P, Stenner F, Hirschi A, Vogl U, Lorch A, Tsantoulis P, Aeppli S, Erdmann A, Maranta AF, Fankhauser C, Hötker AM, Pausch AM, Herzig P, Le Gall V, Zippelius A, Chiquet S, Rothschild SI, Rentsch CA
doi: 10.1200/JCO-26-00845
Genitourinary Cancer
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
N Engl J Med
Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, Bjerggaard Jensen J, Makaroff L, Jiang S, Ku JH, Park SH, Reig Torras O, Ye D, Maruzzo M, Necchi A, Morales-Barrera R, Giunta EF, Lee JL, Tortora G, Ürün Y, Dolowy L, Erdem D, Pinto A, Grando F, Zou W, Assaf ZJ, Vuky J, Degaonkar V, Steinberg EE, Bellmunt J, Gschwend JE, IMvigor011 Investigators
doi: 10.1056/NEJMoa2511885
COMMENTED
Genitourinary Cancer
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Bladder Cancer
Kaufmann E, Aeppli S, Affentranger A, Arnold N, Arnold W, Aschwanden F, Balermpas P, Beyer J, Bieri U, Boormanns J, Cathomas R, Bari B, Dressler M, Engeler DS, Erdmann A, Gallina A, Gomez S, Guckenberger M, Herrmann T, Hermanns T, Lucca I, John H, Kessler TM, Klein J, Laouiti M, Lauffer D, Lerner SP, Mattei A, Müntener M, Nguyen D, Niederberger P, Papachristofilou A, Prause L, Putora PM, Reinhardt K, Salati E, Sèbe P, Shelan M, Sigg S, Strebel RT, Templeton AJ, Vogl U, Wettstein MS, Wyler S, Zihler D, Zilli T, Zwahlen D, Roth B, Fankhauser CD
doi: 10.1177/23523735251410823
Genitourinary Cancer
Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer
J Clin Oncol
Murthy V, Maitre P, Pal M, Arora A, Phurailatpam R, Sharma R, Gudipudi D, Rajappa S, Pujari L, Bandekar B, Joseph D, Kannan S, Krishnatry R, Misra A, Joshi A, Noronha V, Prabhash K, Menon S, Bakshi G, Prakash G
doi: 10.1200/JCO-25-02093
COMMENTED
Genitourinary Cancer
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Clin Oncol
Gore JL, Wolff EM, Nash MG, Comstock BA, Gilbert SM, Chang SS, Chisolm S, MacLean DB, Wright JL, Kates MR, Pohar KS, Guzzo TJ, Bivalacqua TJ, Nepple KG, Montgomery JS, Scarpato KR, Woldu SL, Master VA, Chen DYT, Mossanen M, Daneshmand S, O'Neil BB, Tyson MD, Westerman ME, Kamat AM, Mansour AM, Chamie K, Riggs SB, Kukreja JB, Modi PK, Garg T, Peyton CC, Nix JW, Dickstein R, Gadzinski AJ, Sankin A, Shore ND, Lane BR, Bassett JC, Patel S, Morris DS, Macleod LC, Lee EK, Ritch CR, Follmer KM, Lee JR, Kim SM, Kessler LG, Smith AB, CISTO Collaborative group
doi: 10.1200/JCO-25-01324
ESMO 2026
Genitourinary Cancer